文献速递前列腺增生与排尿功能障碍膀胱癌与上尿路尿路上皮癌

脊髓损伤后神经源性膀胱扩大成形术的长期结局

Long-term outcomes of augmentation cystoplasty for neurogenic lower urinary tract dysfunction after spinal cord injury.
PubMed 文献 · BJU Int · 2026-10-09

该回顾性队列纳入1988至2018年间70例脊髓损伤伴难治性神经源性下尿路功能障碍、接受膀胱扩大成形术的患者,平均随访19年。术后最大膀胱测压容量与最大逼尿肌压力显著改善,67%患者达到控尿,但长期可见尿路结石、腺癌等并发症。

要点

  • 膀胱扩大成形术可持久改善脊髓损伤患者的膀胱容量、储尿期压力与控尿。
  • 术后需终身结构化随访,警惕尿路结石、恶性肿瘤与自发性穿孔。
  • 部分患者术后加用逼尿肌内A型肉毒毒素注射可能进一步获益。

核心结论

  • 膀胱扩大成形术为脊髓损伤后难治性神经源性下尿路功能障碍患者提供持久的膀胱容量、储尿压力与控尿改善,并持续保护上尿路。
  • 尽管存在值得注意的远期并发症,配合结构化终身随访,结局仍属良好。
  • 辅助性逼尿肌内A型肉毒毒素注射可使部分患者额外获益,可能优化长期膀胱动力学。

研究设计与样本

  • 单中心回顾性队列研究,纳入1988至2018年间在某三级转诊中心接受膀胱扩大成形术的脊髓损伤患者。
  • 共纳入70例患者(47例男性、23例女性),平均(范围)随访19(5-36)年。
  • 纳入要求为难治性神经源性下尿路功能障碍,且有记录的尿动力学异常,并且保守与微创治疗失败。
  • 统计比较采用配对t检验。
  • 预设亚组分析评估膀胱扩大成形术后行逼尿肌内A型肉毒毒素注射的结局。

主要发现

  • 膀胱扩大成形术后最大膀胱测压容量由155 mL升至490 mL(P < 0.001)。
  • 最大逼尿肌压力由72 cmH2O降至19 cmH2O(P < 0.001)。
  • 67%的患者达到控尿,另有24%仅偶有漏尿。
  • 术后反复尿路感染与抗胆碱能药物使用减少,多数合并膀胱输尿管反流的患者反流改善。
  • 远期并发症包括尿路结石10%、恶性肿瘤4%(均为腺癌)、自发性穿孔1.5%;需辅助肉毒毒素者(n = 18)在部分分析中最大膀胱测压容量与最大逼尿肌压力显著改善(P = 0.025和P = 0.009)。

临床怎么用

  • 对脊髓损伤后难治性神经源性下尿路功能障碍、保守及微创治疗失败者,可考虑膀胱扩大成形术以改善储尿功能与控尿。
  • 术后应坚持终身结构化随访,监测尿路结石、恶性肿瘤与自发性穿孔等远期并发症。
  • 对术后膀胱动力学仍不理想的部分患者,可评估逼尿肌内A型肉毒毒素注射作为辅助治疗。

局限性

  • 为单中心回顾性队列研究,样本量70例。
  • 随访时间跨度大(1988至2018年),期间诊疗实践可能变化。
  • 肉毒毒素亚组分析样本量小(n = 18),且仅在部分分析中观察到显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate long-term urodynamic, clinical, and complication outcomes following augmentation cystoplasty (AC) in patients with spinal cord injury (SCI) and refractory neurogenic lower urinary tract dysfunction (NLUTD), and to assess the role of adjunctive intradetrusor onabotulinumtoxinA injections. PATIENTS AND METHODS: We performed a retrospective cohort study of patients with SCI undergoing AC at a tertiary referral centre between 1988 and 2018. Inclusion required refractory NLUTD with documented urodynamic abnormalities and failure of conservative and minimally invasive therapies. Pre- and postoperative outcomes included maximum cystometric capacity (MCC), maximum detrusor pressure (MDP), continence status, recurrent urinary tract infections (rUTIs), vesico-ureteric reflux (VUR), and complications. A subgroup analysis evaluated outcomes following post-augmentation intradetrusor onabotulinumtoxinA injections. Statistical comparisons were performed using paired t-tests. RESULTS: A total of 70 patients (47 male, 23 female) were included, with a mean (range) follow-up of 19 (5-36) years. AC resulted in significant improvements in MCC (155-490 mL; P < 0.001) and MDP (72-19 cmH2O; P < 0.001). Continence was achieved in 67% of patients, with a further 24% reporting only occasional leakage. rUTIs and antimuscarinic use decreased postoperatively, and VUR improved in most affected patients. Long-term complications included urolithiasis in 10%, malignancy in 4% (all adenocarcinoma), and spontaneous perforation in 1.5%. In patients requiring adjunctive botulinum toxin (n = 18), significant improvements in MCC and MDP were observed in selected analyses (P = 0.025 and P = 0.009, respectively). CONCLUSION: Augmentation cystoplasty provides durable long-term improvements in bladder capacity, storage pressures, and continence in patients with SCI with refractory NLUTD, with sustained protection of the upper urinary tract. Although associated with notable late complications, outcomes remain favourable with structured lifelong surveillance. Adjunctive intradetrusor onabotulinumtoxinA injections offers additional benefit in a subset of patients and may optimise long-term bladder dynamics.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Tsikopoulos I, Knight S, Furrer MA, et al. Long-term outcomes of augmentation cystoplasty for neurogenic lower urinary tract dysfunction after spinal cord injury. BJU Int. 2026. PMID: 42851250. doi:10.1111/bju.70464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。